Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paromomycin Sulfate

FDA-approved product (capsule, oral), marketed as Humatin, Paromomycin Sulfate.

Registered studies
36
Lab records
3
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paromomycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA06

Repurposing investigation

Paromomycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 2 of 2 lab records
Open Paromomycin Sulfate in ChEMBL Registered studies below
Show the 3 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paromomycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

    NCT07463040 · start 2027-01-01

    Registered record
    Registry ID
    NCT07463040
    Conditions
    Cutaneous Leihmaniasis
    Interventions
    Sodium Stibogluconate (SSG); Miltefosine; Miltefosine + Paromomycin; Liposomal Amphotericin B (LAmB); Pentamidine isethionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2029-08-31
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leihmaniasis
    InterventionSodium Stibogluconate (SSG); Miltefosine; Miltefosine + Paromomycin; Liposomal Amphotericin B (LAmB) +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

    NCT05957978 · start 2024-03-29

    Registered record
    Registry ID
    NCT05957978
    Conditions
    Primary Visceral Leishmaniasis
    Interventions
    LXE408; sodium stibogluconate; Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-03-29
    Completion
    2025-11-13
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Visceral Leishmaniasis
    InterventionLXE408; sodium stibogluconate; Paromomycin
    PhasePhase 2
    Registry statusCompleted

  • Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

    NCT06907498 · start 2024-01-22

    Registered record
    Registry ID
    NCT06907498
    Conditions
    Dientamoeba Fragilis Infection
    Interventions
    Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-01-22
    Completion
    2026-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDientamoeba Fragilis Infection
    InterventionParomomycin
    PhaseNot applicable
    Registry statusRecruiting

  • A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis

    NCT04342715 · start 2022-05-22

    Registered record
    Registry ID
    NCT04342715
    Conditions
    Visceral Leishmaniasis
    Interventions
    Sodium stibogluconate / paramomycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-05-22
    Completion
    2026-03-31
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionSodium stibogluconate / paramomycin
    PhaseNot recorded
    Registry statusActive not recruiting

  • Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

    NCT03829917 · start 2019-02-01

    Registered record
    Registry ID
    NCT03829917
    Conditions
    Cutaneous Leishmaniasis, American
    Interventions
    Miltefosine and Paromomycin; miltefosine; paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2020-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis, American
    InterventionMiltefosine and Paromomycin; miltefosine; paromomycin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Oral Antibiotic Prophylaxis in Colorectal Surgery

    NCT03759886 · start 2018-12-17

    Registered record
    Registry ID
    NCT03759886
    Conditions
    Surgical Site Infection; Anastomotic Leak
    Interventions
    Paromomycin Sulfate Powder
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-12-17
    Completion
    2020-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection; Anastomotic Leak
    InterventionParomomycin Sulfate Powder
    PhaseNot recorded
    Registry statusUnknown

  • Short Course Regimens for Treatment of PKDL (Sudan)

    NCT03399955 · start 2018-05-09

    Registered record
    Registry ID
    NCT03399955
    Conditions
    PKDL - Post-Kala-Azar Dermal Leishmanioid
    Interventions
    Paromomycin; Ambisome; Miltefosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-05-09
    Completion
    2022-05-01
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPKDL - Post-Kala-Azar Dermal Leishmanioid
    InterventionParomomycin; Ambisome; Miltefosine
    PhasePhase 2
    Registry statusUnknown

  • Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

    NCT03129646 · start 2018-01-24

    Registered record
    Registry ID
    NCT03129646
    Conditions
    Visceral Leishmaniasis
    Interventions
    Miltefosine; Paromomycin; Sodium stibogluconate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2020-12-11
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionMiltefosine; Paromomycin; Sodium stibogluconate
    PhasePhase 3
    Registry statusCompleted

  • Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

    NCT03096457 · start 2017-04-15

    Registered record
    Registry ID
    NCT03096457
    Conditions
    Leishmaniasis, Cutaneous; Leishmania Braziliensis Complex; Leishmaniasis, American; Leishmaniasis; American, Cutaneous
    Interventions
    Paromomycin Sulfate; Pentamidine Isethionate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-04-15
    Completion
    2018-04-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous; Leishmania Braziliensis Complex; Leishmaniasis, American; Leishmaniasis +1 more
    InterventionParomomycin Sulfate; Pentamidine Isethionate; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

    NCT01140191 · start 2013-09

    Registered record
    Registry ID
    NCT01140191
    Conditions
    Leishmaniasis, Cutaneous
    Interventions
    WR 279,396
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-09
    Completion
    2014-09
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous
    InterventionWR 279,396
    PhasePhase 2
    Registry statusTerminated

  • WR 279,396 for the Treatment of Cutaneous Leishmaniasis

    NCT01988909 · start 2013-09

    Registered record
    Registry ID
    NCT01988909
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    WR 279,396
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionWR 279,396
    PhasePhase 2
    Registry statusCompleted

  • Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

    NCT01790659 · start 2013-05

    Registered record
    Registry ID
    NCT01790659
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    WR 279,396; Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-05
    Completion
    2016-01
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionWR 279,396; Paromomycin
    PhasePhase 3
    Registry statusCompleted

  • The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit

    NCT01780909 · start 2013-02

    Registered record
    Registry ID
    NCT01780909
    Conditions
    Concentration-Time Profiles in Stomach & Intestine.
    Interventions
    Paromomycin Sulfate Fasted State; Paromomycin Sulfate Fed State; Paromomycin Sulfate w/ domperidone; Paromomycin Sulfate w/ loperamide HCl
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2017-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConcentration-Time Profiles in Stomach & Intestine.
    InterventionParomomycin Sulfate Fasted State; Paromomycin Sulfate Fed State; Paromomycin Sulfate w/ domperidone; Paromomycin Sulfate w/ loperamide HCl
    PhaseNot applicable
    Registry statusUnknown

  • WR 279,396 Open Label Treatment Protocol in Tunisia

    NCT01494350 · start 2011-12

    Registered record
    Registry ID
    NCT01494350
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    WR 279,396 topical cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2012-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionWR 279,396 topical cream
    PhasePhase 2
    Registry statusTerminated